DK0553178T3 - Bifasiske afgivelsesformuleringer til lipofile lægemidler - Google Patents

Bifasiske afgivelsesformuleringer til lipofile lægemidler

Info

Publication number
DK0553178T3
DK0553178T3 DK91918238.6T DK91918238T DK0553178T3 DK 0553178 T3 DK0553178 T3 DK 0553178T3 DK 91918238 T DK91918238 T DK 91918238T DK 0553178 T3 DK0553178 T3 DK 0553178T3
Authority
DK
Denmark
Prior art keywords
pct
active substance
fatty acid
date
pharmaceutically active
Prior art date
Application number
DK91918238.6T
Other languages
English (en)
Inventor
Stephen George Barnwell
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Application granted granted Critical
Publication of DK0553178T3 publication Critical patent/DK0553178T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DK91918238.6T 1990-10-19 1991-10-18 Bifasiske afgivelsesformuleringer til lipofile lægemidler DK0553178T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022788A GB9022788D0 (en) 1990-10-19 1990-10-19 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK0553178T3 true DK0553178T3 (da) 1995-07-24

Family

ID=10684032

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91918238.6T DK0553178T3 (da) 1990-10-19 1991-10-18 Bifasiske afgivelsesformuleringer til lipofile lægemidler

Country Status (21)

Country Link
US (1) US5391377A (da)
EP (1) EP0553178B1 (da)
JP (1) JP3276368B2 (da)
KR (1) KR100188642B1 (da)
AT (1) ATE122881T1 (da)
AU (1) AU656924B2 (da)
BG (1) BG61383B1 (da)
CA (1) CA2093206C (da)
CZ (1) CZ282822B6 (da)
DE (1) DE69110052T2 (da)
DK (1) DK0553178T3 (da)
ES (1) ES2073177T3 (da)
FI (1) FI104408B (da)
GB (1) GB9022788D0 (da)
HK (1) HK85296A (da)
HU (2) HUT64215A (da)
NO (1) NO305505B1 (da)
RO (1) RO114739B1 (da)
RU (1) RU2121344C1 (da)
SK (1) SK279845B6 (da)
WO (1) WO1992006680A1 (da)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
GB9325445D0 (en) * 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
ES2154806T3 (es) * 1995-02-06 2001-04-16 Elan Pharma Int Ltd Formulaciones de compuestos como dispersiones de nanoparticulas en aceites o acidos grasos digeribles.
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6024980A (en) * 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
US6093420A (en) 1996-07-08 2000-07-25 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20030008919A1 (en) * 1999-06-03 2003-01-09 Jean-Baptiste Roullet Use of retinoids to treat high blood pressure and other cardiovascular disease
WO1999034806A1 (en) 1998-01-08 1999-07-15 The Regents Of The University Of California KINESIN MOTOR MODULATORS DERIVED FROM THE MARINE SPONGE $i(ADOCIA)
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
RU2257917C2 (ru) 1998-12-11 2005-08-10 Фармасолюшнз, Инк. Самоэмульгирующиеся композиции для плохорастворимых в воде лекарственных препаратов
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
JP2004501099A (ja) * 2000-05-11 2004-01-15 フアルマシア　コーポレイション アルドステロン頂点位相時の放出のためのアルドステロンアンタゴニスト組成物
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
ATE419840T1 (de) * 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040077621A1 (en) * 2002-08-08 2004-04-22 Academia Sinica Antioxidants
US20040248850A1 (en) * 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
DE602005015679D1 (de) * 2004-01-14 2009-09-10 Lavipharm Lab Inc Transdermale abgabevorrichtung für dihydropyridin-artige calcium-antagonisten mit 2 fettsäuren
MXPA06009054A (es) * 2004-02-11 2007-04-16 Athpharma Ltd Composiciones cronoterapeuticas y metodos de su uso.
EP1766389A4 (en) 2004-05-12 2008-08-27 Inst Medical W & E Hall CELL ISOLATION PROCEDURE
US8119601B2 (en) * 2005-03-10 2012-02-21 Ben-Gurion University Of The Negev Research And Development Authority Ltd. Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
MX2007013430A (es) 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
WO2006135985A1 (en) 2005-06-24 2006-12-28 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
WO2007082352A1 (en) 2006-01-20 2007-07-26 Child Health Research Institute Inc Method of treatment, prophylaxis and diagnosis of pathologies of the bone
US8440788B2 (en) * 2006-04-06 2013-05-14 Ben-Gurion University Of The Negev Research And Development Authority Ltd. N-terminal VDAC variants and uses thereof
WO2007123153A1 (ja) * 2006-04-19 2007-11-01 Ono Pharmaceutical Co., Ltd. 経口投与用カプセル
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
WO2008015959A1 (fr) * 2006-08-01 2008-02-07 Otsuka Pharmaceutical Co., Ltd. Composition pharmaceutique permettant une meilleure absorption d'une substance pharmacologiquement active
BRPI0718320A2 (pt) * 2006-10-27 2013-11-26 Janssen Pharmaceutica Nv Composições farmacêuticas secas granuladas e métodos para produzir as mesmas.
CA2691539C (en) * 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Modified toxins
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
AU2008296478B9 (en) * 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2195340A4 (en) 2007-08-28 2011-05-11 Uab Research Foundation SYNTHETIC APOLIPOPROTEIN E-IMITATING POLYPEPTIDES AND METHOD OF USE
PT2954932T (pt) * 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
AU2009247656A1 (en) * 2008-05-12 2009-11-19 Capsugel Belgium Nv Improved capsule with air-vents
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP3281637A1 (en) 2009-08-17 2018-02-14 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US9249189B2 (en) 2010-01-18 2016-02-02 Albany Medical College Alpha-fetoprotein “ring and tail” peptides
PT2608809T (pt) 2010-08-27 2019-08-26 Gilead Biologics Inc Anticorpos para a metaloproteinase 9 da matriz
ES2564358T3 (es) 2010-10-15 2016-03-22 The Trustees Of Columbia University In The City Of New York Genes relacionados con la obesidad y sus proteínas y usos de los mismos
AU2012249301A1 (en) 2011-04-29 2013-11-21 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
WO2013049749A2 (en) 2011-09-29 2013-04-04 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
JP6067756B2 (ja) 2012-02-29 2017-01-25 ギリアード バイオロジックス， インコーポレイテッド マトリックスメタロプロテイナーゼ９に対する抗体
CN104203263A (zh) 2012-03-01 2014-12-10 耶达研究与发展有限公司 利用HSP60衍生肽再生胰岛β细胞
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
JP2015524397A (ja) 2012-07-20 2015-08-24 ラトローブ ユニヴァーシティ 診断及び処置の方法
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP2996706B1 (en) 2013-03-14 2019-07-31 UAB Research Foundation Apolipoprotein mimetics and uses thereof
NZ631098A (en) 2013-03-15 2016-09-30 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
SG11201507287SA (en) 2013-03-15 2015-10-29 Univ California Peptides having reduced toxicity that stimulate cholesterol efflux
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
WO2015011711A1 (en) 2013-07-25 2015-01-29 The National Institute for Biotechnology in the Negev Ltd. Short peptides derived from vdac1, compositions and methods of use thereof
WO2015092792A1 (en) 2013-12-20 2015-06-25 Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. Pro-angiogenic peptides and peptide conjugates
EP3110847A1 (en) 2014-02-27 2017-01-04 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9 and methods of use thereof
AU2015274987A1 (en) 2014-06-11 2016-11-24 Gilead Sciences, Inc. Methods for treating cardiovascular diseases
AU2015291155B2 (en) 2014-07-17 2019-02-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antagonists of neurokinin B in fish reproduction
US10793614B2 (en) 2014-07-17 2020-10-06 Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. Antagonists of fish reproduction
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US10617738B2 (en) 2015-10-27 2020-04-14 The University Of Queensland Mammalian EphA4 polypeptide derivatives lacking one or more N-glycosylation sites and method of use thereof
WO2017083700A1 (en) 2015-11-13 2017-05-18 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
WO2017106566A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
EP3440113A1 (en) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
US11590203B2 (en) 2017-01-30 2023-02-28 Hudson Institute of Medical Research Method of treatment ovarian cancer
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
BR112020008927A2 (pt) 2017-11-08 2020-10-20 Neon Therapeutics, Inc. composições e métodos de fabricação de células t
JP2023518822A (ja) 2020-03-26 2023-05-08 ピーエルエックス オプコ インコーポレイテッド ｐＨ依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
US20230374455A1 (en) 2020-08-13 2023-11-23 Biontech Us Inc. T cell manufacturing compositions and methods
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600639A (en) * 1978-05-23 1981-10-21 Kali Chemie Pharma Gmbh Medicament preparation having resorption properties and method of producing the same
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
EP0351897A3 (en) * 1988-06-17 1990-03-21 The Procter & Gamble Company Skin penetration system for salts of amine-functional drugs
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
HK85296A (en) 1996-05-24
CZ64193A3 (en) 1994-01-19
SK279845B6 (sk) 1999-04-13
US5391377A (en) 1995-02-21
ATE122881T1 (de) 1995-06-15
CA2093206C (en) 2002-01-29
AU8731591A (en) 1992-05-20
FI931745A (fi) 1993-04-16
NO931410D0 (no) 1993-04-16
NO931410L (no) 1993-04-16
FI104408B (fi) 2000-01-31
FI931745A0 (fi) 1993-04-16
KR100188642B1 (ko) 1999-06-01
HU211617A9 (en) 1995-12-28
DE69110052D1 (de) 1995-06-29
HU9301121D0 (en) 1993-07-28
AU656924B2 (en) 1995-02-23
CZ282822B6 (cs) 1997-10-15
KR930701989A (ko) 1993-09-08
GB9022788D0 (en) 1990-12-05
NO305505B1 (no) 1999-06-14
JP3276368B2 (ja) 2002-04-22
BG97644A (bg) 1994-04-29
DE69110052T2 (de) 1995-10-05
CA2093206A1 (en) 1992-04-20
WO1992006680A1 (en) 1992-04-30
ES2073177T3 (es) 1995-08-01
RU2121344C1 (ru) 1998-11-10
EP0553178B1 (en) 1995-05-24
SK36393A3 (en) 1993-07-07
BG61383B1 (en) 1997-07-31
JPH06502143A (ja) 1994-03-10
EP0553178A1 (en) 1993-08-04
RO114739B1 (ro) 1999-07-30
HUT64215A (en) 1993-12-28

Similar Documents

Publication Publication Date Title
DK0553178T3 (da) Bifasiske afgivelsesformuleringer til lipofile lægemidler
RU93048157A (ru) Фармацевтическая композиция двухфазного действия с высвобождением для липофильных лекарственных препаратов, способ ее получения, применение композиции для лечения заболеваний
Pastore et al. Transdermal patches: history, development and pharmacology
AR012854A1 (es) Una composicion de suministro de droga para la liberacion controlada de un ingrediente activo en el ambiente estomacal por un periodo de tiempoprolongado, una composicion farmaceutica que la comprende, el uso de dicha composicion en la fabricacion de un medicamento, un proceso para la preparacion
JP2009515910A5 (da)
US20040202705A1 (en) Transdermal administration of huperzine
DK1341527T3 (da) Farmaceutisk præparat omfattende et aktivstof dispergeret på en matrix
IT1200178B (it) Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
NO20014719D0 (no) Orale farmasöytiske preparater inneholdende lang-kjedete triglyserider og lipofile overflateaktive midler
DK1189620T3 (da) Formulering indeholdende testosteronundecanoat og amerikansk olie
PT1256339E (pt) Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
EP1962821A1 (en) Transdermal administration of active agents , in particular diclofenac
JP2005511725A (ja) 化合物の経皮輸送
EP1575555B1 (en) Formulations of finasteride
PARKER Efficacy of nitroglycerin patches: fact or fancy?
JPS5576816A (en) Drug for medicinal fatty liver
Benson et al. Optimisation of Drug Delivery: 4. Transdermal Drug Delivery
DE69803772D1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
JP2002520269A5 (da)
DE59908258D1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform
GEP20063804B (en) Once-a-day oxycodone formulations
UA86516C2 (ru) Ветеринарная биологически активная добавка липосомальной формы и способ репаративной терапии в гепатологии
JPS61243016A (ja) 柱状の有効成分含有部分をもつ錠剤
CO5380015A1 (es) Una forma de unidad de dosis farmaceutica del tipo del tipo de capsulas rigidas que contiene clonixinato de lisina, un procedimiento para su preparacion y el uso de dicha unidad de dosis como analgesico y/o antiinflamatorio